SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-21-014032
Filing Date
2021-02-24
Accepted
2021-02-24 20:10:27
Documents
2
Period of Report
2021-02-24

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 6843
2 EX-24 DOCUMENT attachment1.htm EX-24 2141
  Complete submission text file 0001209191-21-014032.txt   10529
Mailing Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080 650-266-3500
SUNESIS PHARMACEUTICALS INC (Issuer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O REGULUS THERAPEUTICS INC. 10614 SCIENCE CENTER DRIVE SAN DIEGO CA 92121
Business Address
Chevallard Daniel R. (Reporting) CIK: 0001706176 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-51531 | Film No.: 21675855